PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood

• Publication date

  2009-03-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2008-06-160713PMID 19168795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13

  2008cited by this paper
• Enzastaurin

  2007cited by this paper
• Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation

  2007cited by this paper
• CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC.

  2007cited by this paper
• B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.

  2007cited by this paper
• Protein kinase C and other diacylglycerol effectors in cancer

  2007cited by this paper
• Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL

  2006cited by this paper
• Regulation of Akt/PKB by phosphatidylinositol 3‐kinase‐dependent and ‐independent pathways in B‐cell chronic lymphocytic leukemia cells: role of protein kinase Cβ

  2006cited by this paper
• Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

  2006cited by this paper
• B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.

  2006cited by this paper
• Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo.

  2006cited by this paper
• The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

  2005cited by this paper
• Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

  2004cited by this paper
• Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

  2002cited by this paper
• The protooncogene TCL1 is an Akt kinase coactivator.

  2000cited by this paper
• Immunodeficiency in Protein Kinase Cβ-Deficient Mice

  1996cited by this paper
• Immunodeficiency in protein kinase cbeta-deficient mice.

  1996cited by this paper

• PKCβ inhibitor MS-553 displays preclinical efficacy in both treatment-naïve and BTK inhibitor-resistant Chronic Lymphocytic Leukemia.

  2025cites this paper
• Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ.

  2025cites this paper
• Protein Kinase C Family: Structures, Biological Functions, Diseases, and Pharmaceutical Interventions

  2025cites this paper
• Oxidative Stress and ROS Link Diabetes and Cancer

  2024cites this paper
• Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity

  2022cites this paper
• PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling

  2022influential citation
• Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential

  2022cites this paper
• Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice

  2022cites this paper
• Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients

  2021cites this paper
• Viral Proteins as Emerging Cancer Therapeutics

  2021cites this paper
• Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia

  2021cites this paper
• The Modes of Dysregulation of the Proto-Oncogene T-Cell Leukemia/Lymphoma 1A

  2021cites this paper
• The Role of Calcium Signaling in Regulation of Epithelial-Mesenchymal Transition

  2020cites this paper
• Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia

  2020cites this paper
• A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations

  2020cites this paper
• Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?

  2020cites this paper
• Targeting the mTORC2 signaling complex in B cell malignancies

  2019cites this paper
• Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia

  2019cites this paper
• B-cell specific IRF4 deletion accelerates Chronic Lymphocytic Leukemia development by enhanced tumor immune evasion.

  2019cites this paper
• New roles for B cell receptor associated kinases: when the B cell is not the target

  2019cites this paper
• Enzastaurin inhibits ABCB 1 mediated drug efflux independently of effects on protein kinase C signalling and the cellular

  2019cites this paper
• Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development

  2018cites this paper
• BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation

  2018cites this paper
• PI3K p110&dgr; inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

  2018cites this paper
• MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia.

  2017cites this paper
• NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

  2017cites this paper
• Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells

  2017cites this paper
• Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

  2017cites this paper
• LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.

  2016cites this paper
• TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia

  2016cites this paper
• Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells

  2015cites this paper
• HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells

  2015cites this paper
• Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model

  2015cites this paper
• The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

  2015cites this paper
• Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.

  2015cites this paper
• Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes

  2015cites this paper
• Disruption of pre-B-cell receptor signaling jams the WNT/β-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines.

  2015cites this paper
• Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status

  2015cites this paper
• Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

  2014cites this paper
• Protein kinase C in cellular transformation: a valid target for therapy?

  2014cites this paper
• 1 Protein Kinase C ( PKC ) expression is deregulated in chronic lymphocytic leukemia

  2014cites this paper
• How the microenvironment wires the natural history of chronic lymphocytic leukemia.

  2014cites this paper
• Protein kinase C expression is deregulated in chronic lymphocytic leukemia

  2014cites this paper
• PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

  2014cites this paper
• Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia.

  2014cites this paper
• Targeting pathological B cell receptor signalling in lymphoid malignancies

  2013cites this paper
• B-cell receptor signaling as a driver of lymphoma development and evolution.

  2013cites this paper
• Novel Bruton’s tyrosine kinase inhibitors currently in development

  2013cites this paper
• Identifying CLL antigens for future combinational therapy.

  2013cites this paper
• Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

  2013cites this paper
• Protein kinase C expression is deregulated in chronic lymphocytic leukemia

  2013cites this paper
• Novel Therapies for T-cell Lymphomas

  2013cites this paper
• Identification of LCK as a key mediator of B cell receptor (BCR)signalling in chronic lymphocytic leukaemia (CLL)

  2013cites this paper
• Verstärkung der Zytotoxizität der anti-CD22 Immuntoxine durch Bryostatin 1 in B-Zelllymphomen

  2013influential citation
• Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia

  2012cites this paper
• B lymphoid malignancies: insights from mouse models

  2012cites this paper
• Mouse Models of Chronic Lymphocytic Leukemia

  2012cites this paper
• Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia

  2012cites this paper
• Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells

  2012cites this paper
• Protein Kinase C-Beta Inhibition Induces Apoptosis and Inhibits Cell Cycle Progression in Acquired Immunodeficiency Syndrome–Related Non-Hodgkin Lymphoma Cells

  2012influential citation
• Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

  2012cites this paper
• A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.

  2012cites this paper
• The role of B cell receptor stimulation in CLL pathogenesis.

  2012cites this paper
• The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion

  2012cites this paper
• Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia.

  2011cites this paper
• Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL

  2011cites this paper
• The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β.

  2011cites this paper
• Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C𝛃 inhibitor

  2011cites this paper
• Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

  2011cites this paper
• A novel bisindolymaleimide derivative (WK234) inhibits proliferation and induces apoptosis through the protein kinase Cβ pathway, in chronic myelogenous leukemia K562 cells

  2011cites this paper
• Aberrantly activated anti‐apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets

  2011cites this paper
• Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.

  2010cites this paper
• The TCL1 mouse as a model for chronic lymphocytic leukemia.

  2010cites this paper
• Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

  2010cites this paper
• Recruitment of PKC-βII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70

  2010cites this paper
• Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

  2010cites this paper
• microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

  2010cites this paper
• Riding the 2-edged sword.

  2010cites this paper
• The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.

  2010cites this paper
• Targeting CK 2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

  2010cites this paper
• Presentation of tumour antigens by dendritic cells and challenges faced.

  2010cites this paper
• Immobilization of protein kinase C into cypovirus polyhedra.

  2010cites this paper
• Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.

  2010cites this paper
• An overview of chronic lymphocytic leukaemia biology.

  2010cites this paper
• The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression

  2009cites this paper
• High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

  2009cites this paper